Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc., trading under the ticker UPTD on Nasdaq, filed an 8-K with the SEC on July 19, 2023, marking a notable disclosure event in its post-combination life as a publicly listed clinical-stage biopharmaceutical company. Estrella reached the public markets through a SPAC transaction, operating within the healthcare and immunotherapy sector with a focus on cancer treatment. The July 2023 filing represents one of several material event disclosures the company submitted following its transition from blank-check structure to an operating public entity. Investors and analysts tracking SPAC-origin biopharma names can access full filing timelines, transaction history, and sponsor details for UPTD on SpacDesk — sign up at SpacDesk.com for complete data coverage.